Patents Assigned to Ma'at
  • NOGO Receptor Binding Protein
    Publication number: 20120230979
    Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, John McCoy, R. Blake Pepinsky, Daniel H.S. Lee
  • Neublastin variants
    Patent number: 8263553
    Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: September 11, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Anthony Rossomando, Laura Silvian, R. Blake Pepinsky
  • Methods Relating to Peripheral Administration of Nogo Receptor Polypeptides
    Publication number: 20120219567
    Abstract: This invention relates to methods of treating diseases involving accumulation of A? plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of A? peptide and enhancing A? peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of A? plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 30, 2012
    Applicants: Biogen Idec MA Inc., Yale University
    Inventors: Stephen M. Strittmatter, Daniel H.S. Lee
  • IMPLANT EXTRACTION METHOD AND TREPHINE DRILL BIT FOR ENABLING THE EXTRACTION
    Publication number: 20120203232
    Abstract: A trephine drill bit comprising a body and a tip connected to the body, wherein the tip includes a reduced area having a smaller diameter than the body, the reduced area ending in a stop to indicate when the trephine drill bit should no longer be introduced. A method is also disclosed.
    Type: Application
    Filed: April 16, 2012
    Publication date: August 9, 2012
    Applicant: Biotechnology Institute, I Mas D, S.L.
    Inventor: Eduardo ANITUA ALDECOA
  • ADAPTIVE ELECTRONICALLY STEERABLE ARRAY (AESA) SYSTEM FOR MULTI-BAND AND MULTI-APERTURE OPERATION AND METHOD FOR MAINTAINING DATA LINKS WITH ONE OR MORE STATIONS IN DIFFERENT FREQUENCY BANDS
    Publication number: 20120200449
    Abstract: Embodiments of an adaptive electronically steerable array (AESA) system suitable for use on a vehicle and method for communicating are generally described herein. In some embodiments, the AESA system includes a plurality of arrays of radiating elements and control circuitry to configure the arrays for multi-band and multi-aperture operations to maintain data links with communication stations.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 9, 2012
    Applicant: Raytheon Company- Waltham, MA
    Inventor: Michael S. Bielas
  • Cripto Blocking Antibodies and Uses Thereof
    Publication number: 20120195912
    Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Application
    Filed: August 19, 2011
    Publication date: August 2, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20120195884
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Application
    Filed: September 23, 2011
    Publication date: August 2, 2012
    Applicants: Biogen Idec MA Inc., Elan Pharmaceuticals, Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin Mcdaid Barbour, Julie Elizabeth Taylor
  • Treatment for Multiple Sclerosis
    Publication number: 20120196931
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 2, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Matvey E. LUKASHEV, Gilmore O'Neill
  • Detection and quantitation of cyclodextrins
    Patent number: 8232064
    Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: July 31, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Zoran Sosic, Rulin Qian, James Ahern, Rohin Mhatre
  • BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS
    Publication number: 20120190649
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: August 5, 2010
    Publication date: July 26, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Recombinant anti-VLA4 antibody molecules
    Patent number: 8226950
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: July 24, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Methods for Inhibiting Yellow Color Formation in a Composition
    Publication number: 20120183531
    Abstract: The present invention is related to methods for preventing or retarding (i.e., inhibiting) yellow color or peroxide formation in a composition. The present invention is also related to methods of reducing or decreasing the amount of yellow color or peroxide in a composition. More specifically, the present invention relates to the use of an antioxidant, an oxygen scavenger, pH, a chelating agent, and/or at least two factors in the methods of the invention. The present invention is also related to methods for predicting the rate of yellow color or peroxide formation in a composition.
    Type: Application
    Filed: July 13, 2010
    Publication date: July 19, 2012
    Applicant: BIOGEN IDEE MA INC
    Inventors: Karin Lucas, Kevin Maloney
  • ANTIBODIES TO VLA-1
    Publication number: 20120177638
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: November 15, 2011
    Publication date: July 12, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Neurotrophic factors and methods of use thereof
    Patent number: 8217146
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: July 10, 2012
    Assignees: Biogen Idec MA Inc., NsGene A/S
    Inventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
  • TREATMENT OF NEURODEGENERATION AND NEUROINFLAMMATION
    Publication number: 20120165404
    Abstract: Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroinflammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.
    Type: Application
    Filed: April 29, 2010
    Publication date: June 28, 2012
    Applicant: Biogen Idec MA Inc.
    Inventor: Matvey Lukashev
  • KIM-1 antibodies for treatment of TH2-mediated conditions
    Patent number: 8206705
    Abstract: Compositions and methods for treating Th2- and ThI-mediated disease are provided.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: June 26, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Paul Rennert, Patricia McCoon, Veronique Bailly, Alexey Lugovskoy
  • HETEROARYL BTK INHIBITORS
    Publication number: 20120157442
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 3, 2010
    Publication date: June 21, 2012
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Minna Bui, Patrick Conlon, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Alexey Ishchenko, Tracy J. Jenkins, Gnanasambandam Kumaravel, Doug Marcotte, Noel Powell, Daniel Scott, Art Taveras, Deping Wang, Min Zhong
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20120157443
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 3, 2010
    Publication date: June 21, 2012
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Control console
    Patent number: D666159
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: August 28, 2012
    Assignee: MA Lighting Technology GmbH
    Inventor: Michael Adenau
  • Control console
    Patent number: D666160
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: August 28, 2012
    Assignee: MA Lighting Technology GmbH
    Inventor: Michael Adenau